Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays

2017 ◽  
Vol 46 (2) ◽  
pp. 299-307 ◽  
Author(s):  
Randolph L. Winter ◽  
Ashley B. Saunders ◽  
Sonya G. Gordon ◽  
Matthew W. Miller ◽  
Geoffrey T. Fosgate ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Cardiac Troponin ◽  
Troponin I ◽  
High Sensitivity ◽  
Cardiac Troponin I ◽  
Valve Disease ◽  
Healthy Dogs

Serial measurements of cardiac troponin I in heart failure secondary to canine mitral valve disease

2019 ◽  
Vol 185 (11) ◽  
pp. 343-343 ◽  
Author(s):  
I-Ping Chan ◽  
San-Yu Wu ◽  
Chao-Chin Chang ◽  
Wen-Ying Chen
Keyword(s):  
Heart Failure ◽  
Mitral Valve ◽  
Medical Treatment ◽  
Mitral Valve Disease ◽  
Cardiac Troponin ◽  
Cardiac Death ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Valve Disease ◽  
Serial Measurements

Serial measurements of cardiac troponin I (cTnI) levels are considered to be better predictors of cardiac death than single-time-point analyses in human medicine. We hypothesised that cTnI levels could reflect the severity of myxomatous mitral valve disease (MMVD), and that serial changes in the cTnI level had a prognostic value in dogs with congestive heart failure (CHF) secondary to MMVD. Seventy-six dogs were initially enrolled and classified by the American College of Veterinary Internal Medicine (ACVIM) staging system. The single-timepoint cTnI concentration in these dogs significantly increased with the ACVIM stage. Twenty-seven dogs with CHF subsequently underwent serial measurement of cTnI levels, and the results showed that those who demonstrated a decrease in cTnI levels from the first to the third visit exhibited a higher risk of cardiac death than did those without such changes (P=0.012). We suspect that the downward trend in cTnI levels may be affected by medical treatment for CHF. In conclusion, although cTnI levels could reflect the severity of MMVD to a certain extent, the serial changes may be affected by medical treatment. Therefore, caution should be exercised when cTnI is used for assessment of the prognosis of CHF secondary to MMVD in dogs.

Serial analysis of serum cardiac troponin I changes and correlation with clinical findings in 46 dogs with mitral valve disease

2014 ◽  
Vol 43 (2) ◽  
pp. 218-225 ◽  
Author(s):  
Zoe S. Polizopoulou ◽  
Christos K. Koutinas ◽  
Anastasia Dasopoulou ◽  
Michael Patsikas ◽  
Malcolm York ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Clinical Findings ◽  
Cardiac Troponin I ◽  
Valve Disease ◽  
Serum Cardiac Troponin

Correlation of serum cardiac troponin I and acute phase protein concentrations with clinical staging in dogs with degenerative mitral valve disease

2015 ◽  
Vol 44 (3) ◽  
pp. 397-404 ◽  
Author(s):  
Zoe S. Polizopoulou ◽  
Christos K. Koutinas ◽  
José J. Cerón ◽  
Asta Tvarijonaviciute ◽  
Silvia Martínez-Subiela ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Acute Phase ◽  
Mitral Valve Disease ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Acute Phase Protein ◽  
Cardiac Troponin I ◽  
Clinical Staging ◽  
Phase Protein ◽  
Serum Cardiac Troponin

Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration

2015 ◽  
Vol 44 (3) ◽  
pp. 420-430 ◽  
Author(s):  
Craig Ruaux ◽  
Katherine Scollan ◽  
Jan S. Suchodolski ◽  
Jörg M. Steiner ◽  
D. David Sisson
Keyword(s):  
Mitral Valve ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Healthy Dogs
Sign in / Sign up

Export Citation Format

Share Document